CC
ALNY icon

Casdin Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Casdin Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,000
Closed -$3.54M – 39
2023
Q3 		$3.54M Buy
+20,000
New +$3.82M 0.39% 28

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Casdin Capital's ALNY Position: Q2 2026 in Review

Casdin Capital held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 75,000 shares worth $22.6M. The position accounts for 1.13% of the portfolio, ranked #18.

Casdin Capital first reported a position in ALNY in Q4 2015 and has held it in 43 quarters since. The position peaked at $189M in Q3 2021. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Casdin Capital held 75,000 shares of Alnylam Pharmaceuticals worth $22.6M as of Q2 2026.
  • Casdin Capital left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 1.13% of Casdin Capital's portfolio in Q2 2026, its #18 holding.
  • Casdin Capital first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
  • Casdin Capital's Alnylam Pharmaceuticals position peaked at $189M in Q3 2021.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.